Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee. Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| HROW | HARROW, INC. | 2025-10-16 18:59:56 | 37.2 | -0.72 | -1.9 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HROW | 0001360214 | HARROW, INC. | US4158581094 | — | 450567010 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 1A BURTON HILLS BLVD | NASHVILLE | TN | — | UNITED STATES | US | 615.733.4731 | 1A BURTON HILLS BLVD, NASHVILLE, TN | 1A BURTON HILLS BLVD, NASHVILLE, TN | HARROW HEALTH, INC. | Pharmaceutical Industry | 2012 | Mark L. Baum | — | http://www.harrow.com/ | 678,000,000 | 36,714,679 | 37,002,136 | Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee. Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing. | 2025-10-10 20:50:02 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 678,000,000 | 214,000,000 | 46.1207 | 35,654,171 | 291,529 | 0.8244 |
| 2023 | 464,000,000 | 305,000,000 | 191.8239 | 35,362,642 | 5,394,893 | 18.0023 |
| 2022 | 159,000,000 | -37,000,000 | -18.8776 | 29,967,749 | 2,937,622 | 10.868 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| John P. Saharek | Chief Executive Officer, President | 2024 | 463,431 | — | 0 | 234,000 | 46,036 | 743,467 |
| Andrew R. Boll | Chief Financial Officer, Corporate Secretary | 2024 | 491,920 | — | 0 | 342,930 | 14,351 | 849,201 |
| Mark L. Baum | Chief Executive Officer | 2024 | 731,120 | — | 0 | 611,618 | 15,752 | 1,358,490 |
| Mark L. Baum | Chief Executive Officer | 2023 | 680,086 | — | 14,150,821 | 421,800 | 3,756 | 15,256,463 |
| John P. Saharek | Chief Commercial Officer, President, Chief Executive Officer | 2023 | 431,463 | — | 5,145,753 | 225,000 | 12,938 | 5,815,154 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 382 |
| 2023 | 315 |
| 2022 | 217 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 199,614,000 | 130,193,000 | 88,595,000 |
| Cost Of Revenue | 49,245,000 | 39,640,000 | 25,383,000 |
| Gross Profit | 150,369,000 | 90,553,000 | 63,212,000 |
| Research And Development Expenses | 12,230,000 | 6,652,000 | 3,050,000 |
| General And Administrative Expenses | 129,064,000 | 83,090,000 | 58,243,000 |
| Operating Expenses | 141,547,000 | 90,122,000 | 61,293,000 |
| Operating Income | 8,822,000 | 431,000 | 1,919,000 |
| Net Income | -17,481,000 | -24,411,000 | -14,086,000 |
| Earnings Per Share Basic | -0.49 | -0.75 | -0.51 |
| Earnings Per Share Diluted | -0.49 | -0.75 | — |
| Weighted Average Shares Outstanding Basic | 35,650,714 | 32,616,777 | 27,460,968 |
| Weighted Average Shares Outstanding Diluted | 35,650,714 | 32,616,777 | — |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 47,247,000 | 74,085,000 | 96,270,000 |
| Marketable Securities Current | — | 8,681,000 | 5,589,000 |
| Accounts Receivable | 20,147,000 | 15,146,000 | 779,000 |
| Inventories | 10,702,000 | 10,867,000 | 6,541,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 3,410,000 | 1,753,000 | 118,000 |
| Total Assets Current | 189,651,000 | 139,482,000 | 118,260,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 3,734,000 | 3,521,000 | 3,486,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 199,320,000 | 172,682,000 | 107,000 |
| Total Assets | 388,971,000 | 312,164,000 | 157,378,000 |
| Accounts Payable | 38,762,000 | 21,424,000 | 6,440,000 |
| Deferred Revenue | 44,000 | 75,000 | 113,000 |
| Short Term Debt | 23,877,000 | 21,201,000 | 10,053,000 |
| Other Liabilities Current | 0 | 89,000 | — |
| Total Liabilities Current | 91,343,000 | 49,344,000 | 18,632,000 |
| Long Term Debt | 262,737,000 | 246,717,000 | 151,773,000 |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 228,331,000 | 192,409,000 | 111,506,000 |
| Total Liabilities | 319,674,000 | 241,753,000 | 130,138,000 |
| Common Stock | 35,000 | 35,000 | 30,000 |
| Retained Earnings | -151,385,000 | -133,904,000 | -109,493,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | 69,652,000 | 70,766,000 | 27,595,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 1,850,000 | 1,530,000 | 1,477,000 |
| Share Based Compensation Expense | 17,619,000 | 15,696,000 | 7,974,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 80,232,000 | 30,344,000 | 1,860,000 |
| Change In Inventories | -165,000 | 4,326,000 | 2,324,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 37,498,000 | 31,795,000 | 1,839,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -22,202,000 | 3,840,000 | 1,705,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | 5,510,000 | — | — |
| Acquisition Of Property Plant And Equipment | 1,595,000 | 1,460,000 | 2,597,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -33,164,000 | -152,553,000 | -1,743,000 |
| Tax Withholding For Share Based Compensation | 1,205,000 | 11,273,000 | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | 64,520,000 | 22,655,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | 55,879,000 | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 28,528,000 | 126,528,000 | 54,141,000 |
| Change In Cash | -26,838,000 | -22,185,000 | 54,103,000 |
| Cash At End Of Period | 47,247,000 | 74,085,000 | 96,270,000 |
| Income Taxes Paid | 374,000 | — | 75,000 |
| Interest Paid | 20,594,000 | 18,887,000 | 6,480,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -0.49 | -0.75 | -0.51 |
| Price To Earnings Ratio | -68.4694 | -14.9333 | -28.9412 |
| Earnings Growth Rate | -34.6667 | 47.0588 | — |
| Price Earnings To Growth Ratio | 1.9751 | -0.3173 | — |
| Book Value Per Share | 1.9438 | 2.1587 | 0.992 |
| Price To Book Ratio | 17.2602 | 5.1882 | 14.8797 |
| Ebitda | 7,529,000 | -1,557,000 | -5,290,000 |
| Enterprise Value | 1,435,448,454.7 | 559,140,902.4 | 470,879,887.68 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 4.1149 | 3.786 | 5.8643 |
| Capital Expenditures | 2,063,000 | 1,565,000 | 1,822,000 |
| Free Cash Flow | -24,265,000 | 2,275,000 | -117,000 |
| Return On Equity | -0.251 | -0.345 | -0.5105 |
| One Year Beta | 2.17 | 0.5743 | 0.6268 |
| Three Year Beta | 0.8705 | 0.6204 | 0.9263 |
| Five Year Beta | 0.984 | 0.8841 | 0.9211 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Pollard Randall E. | CHIEF ACCOUNTING OFFICER | 2025-09-01 | 30,000 | A | 30,000 |
| BAUM MARK L | Director, CHIEF EXECUTIVE OFFICER, 10% owner | 2025-07-21 | 600,000 | A | 3,199,462 |
| BAUM MARK L | Director, CHIEF EXECUTIVE OFFICER, 10% owner | 2025-07-21 | 313,338 | D | 2,886,124 |
| BAUM MARK L | Director, CHIEF EXECUTIVE OFFICER | 2025-07-01 | 889,500 | A | 889,500 |
| BOLL ANDREW R. | CHIEF FINANCIAL OFFICER | 2025-07-01 | 405,750 | A | 405,750 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| RICE HALL JAMES & ASSOCIATES, LLC | 2025-09-30 | 16,077,425 | 333,695 | 48.18 |
| CWM, LLC | 2025-09-30 | 6,000 | 116 | 51.7241 |
| Brookstone Capital Management | 2025-09-30 | 2,205,440 | 45,775 | 48.18 |
| Farther Finance Advisors, LLC | 2025-09-30 | 7,950 | 165 | 48.1818 |
| VOYA INVESTMENT MANAGEMENT LLC | 2025-09-30 | 280,167 | 5,815 | 48.1801 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Jacob Funds Inc. | 2025-08-31 | Institutional Class | JMIGX | 20,547 | 801,333 | 4.9614 |
| Jacob Funds Inc. | 2025-08-31 | Investor Class | JMCGX | 20,547 | 801,333 | 4.9614 |
| Jacob Funds Inc. | 2025-08-31 | Investor Class | JSCGX | 12,814 | 499,746 | 4.9645 |
| Advisors' Inner Circle Fund III | 2025-07-31 | I Shares | KCXIX | 140 | 4,446.4 | 0.0018 |
| Global X Funds | 2025-07-31 | Global X Russell 2000 ETF | RSSL | 16,101 | 511,367.76 | 0.0389 |